Tirzepatide activates two receptors both GLP 1 and GIP (glucose dependent insulinotropic polypeptide)
doi: 10.21608/EJH.2018.7518
Whilst treatment failed to reduce amyloid plaque load, liraglutide did prevent the decline in cerebral glucose metabolism after 26 weeks compared to placebo treatment, which suggests that liraglutide may modify disease progression
What we know about GLP-1s and deprescribing GLP-1s help control blood glucose, promote feelings of fullness, and suppress appetite
If you opt in to GLP-1 Insights, your weight over time appears alongside your sleep trends, activity levels, and recovery data
Most patients notice appetite suppression within 1-2 weeks of starting semaglutide, with measurable weight loss appearing after 4-8 weeks